Xeris Biopharma Holdings, Inc. (XERS): ANSOFF MATRIX [Dec-2025 Updated]

You're looking at Xeris Biopharma Holdings, Inc. with their $285 million to $290 million revenue guidance set for 2025, and you need to know exactly where the growth levers are pulled. As someone who's mapped out strategies for big firms, I've broken down their next moves using the Ansoff Matrix-it's the clearest way to see the risk versus reward for everything from pushing existing drugs harder in current markets to making big bets on new science or geographies. Below, we detail the four concrete paths Xeris Biopharma Holdings, Inc. can take right now to hit those numbers and beyond, so you can see the near-term actions versus the longer-term potential.

Xeris Biopharma Holdings, Inc. (XERS) - Ansoff Matrix: Market Penetration

You're looking at how Xeris Biopharma Holdings, Inc. is driving deeper into its existing markets, which is the core of Market Penetration in the Ansoff Matrix. This strategy relies heavily on maximizing the reach and sales velocity of its current portfolio: Recorlev, Gvoke, and Keveyis.

The momentum from Recorlev is undeniable, showing a 108.6% year-over-year revenue surge in the third quarter of 2025, hitting $37.0 million in net revenue. This growth validates the focus on patient identification for Cushing's syndrome. For the first nine months of 2025, Recorlev net revenue reached $94.0 million, marking an increase of approximately 126% compared to the same period in 2024.

To capitalize on this, Xeris Biopharma Holdings, Inc. is making significant operational investments. Management explicitly stated they are initiating a commercial expansion, planning to nearly double their sales and patient support teams to accelerate Recorlev adoption and prepare for 2026 scale. This investment is reflected in the Selling, General and Administrative (SG&A) expenses, which increased mainly due to higher personnel-related expenses, including investments in the Recorlev commercial organization that began in the third quarter of 2024.

For Gvoke, the goal is clear: push the retail glucagon market share past the 35% mark it held in the fourth quarter of 2024. Gvoke delivered steady, reliable growth in Q3 2025, with net revenue reaching $25.2 million, a 9.6% increase over the prior year, driven by higher volume and favorable net pricing.

Keveyis requires optimization to offset market headwinds. In Q3 2025, Keveyis net revenue was $11.9 million, representing a 2.1% decrease from $12.2 million in Q3 2024, with management citing pricing pressure as the main challenge. Optimizing pricing and access is a direct action to stabilize and defend this existing revenue base.

Expanding the Recorlev patient pool involves targeting physicians who may be missing the diagnosis of Cushing's syndrome, a rare and serious endocrine disease. The company supports prescribers and patients through the Xeris CareConnection™ team for ongoing management.

Here's a look at the Q3 2025 product revenue performance driving these penetration efforts:

The overall commercial execution led Xeris Biopharma Holdings, Inc. to raise its full-year 2025 total revenue guidance to a range of $285 million to $290 million, implying 42% growth at the midpoint compared to the prior year.

Key actions for Market Penetration include:

• Expand Recorlev patient identification efforts.
• Drive Gvoke retail market share past 35%.
• Increase sales and patient support teams by nearly 100%.
• Target undiagnosed Cushing's syndrome patients.
• Optimize Keveyis pricing and access strategies.

The company achieved its first-ever quarterly net income of $0.6 million in Q3 2025, a significant swing from a $15.7 million net loss in Q3 2024.

Xeris Biopharma Holdings, Inc. (XERS) - Ansoff Matrix: Market Development

Market Development for Xeris Biopharma Holdings, Inc. centers on taking existing, approved products into new geographic areas or new patient/procedure segments within established markets. This strategy relies on the established efficacy and formulation advantages of your current portfolio.

Accelerate commercialization of Gvoke (Ogluo) into new European territories.

The European path for Ogluo, the brand name for Gvoke in that region, began with European Commission approval on February 11, 2021, for severe hypoglycemia treatment in patients aged 2 years and older. The initial commercialization strategy involved an exclusive agreement with Tetris Pharma for the European Economic Area, the United Kingdom, and Switzerland. Under that agreement, Xeris Biopharma Holdings, Inc. was positioned to receive up to $71 million in milestone payments plus a royalty on net sales. The Phase 3 study supporting this approval randomized 132 adults with Type 1 diabetes. While the initial launch targets were set for late 2021/mid-2022 in a limited number of countries, the current focus is on expanding this reach. For context on the product line's performance, Gvoke net revenue for the nine months ended September 30, 2025, reached $69.5 million, marking an increase of approximately 17% compared to the same period in 2024. For the first half of 2025, Gvoke net revenue was $44.3 million, a 21% increase year-over-year.

Seek Recorlev regulatory approval in major non-US markets like Canada and Australia.

Recorlev (levoketoconazole) received U.S. Food and Drug Administration approval on December 30, 2021, for endogenous Cushing's syndrome in adults ineligible for or unresponsive to surgery. The U.S. market performance shows significant growth, with Recorlev net revenue reaching $94.0 million for the nine months ended September 30, 2025, representing an increase of approximately 126% compared to the first nine months of 2024. For the first six months of 2025, Recorlev net revenue was $57.0 million, a 138% increase year-over-year. Specific, up-to-date statistical data on the status of Canadian or Australian regulatory submissions and approvals for Recorlev as of late 2025 is not available in the latest filings, but the strong U.S. growth provides a clear financial incentive for this market expansion. The U.S. approval was based on data from a combined study population of 166 patients across two Phase 3 trials.

Partner with international distributors to access the 15 million diabetic patients lacking glucagon protection.

The need for broader glucagon access is significant; in 2021, it was noted that very few diabetes patients on insulin in the EU and UK had glucagon on hand. While the exact figure of 15 million patients lacking protection globally is not confirmed in the latest data, the market for severe hypoglycemia treatment is substantial. The success of the U.S. Gvoke line, which treats severe hypoglycemia in patients aged 2 years and older, shows the potential. In the U.S., Gvoke treatment success rates were demonstrated at 99% in adults and 100% in children in clinical studies. Securing distribution partnerships is key to reaching these underserved populations outside the current commercial footprint.

Launch Gvoke (glucagon) for its diagnostic aid indication in new US hospital systems.

Xeris Biopharma Holdings, Inc. announced the commercial launch of Gvoke VialDx™ (glucagon injection) through a partnership with American Regent, with availability expected in the third quarter of 2025. This product is indicated for intravenous use as a diagnostic aid in adult patients during radiologic examinations to temporarily inhibit gastrointestinal tract movement. The potential market size for this indication is supported by the context of an estimated 20 million gastrointestinal endoscopic procedures performed annually. This launch expands Gvoke's utility beyond severe hypoglycemia treatment, where it is available in pediatric (0.5 mg/0.1 mL) and adult (1.0 mg/0.2 mL) doses.

Explore licensing deals for Keveyis in Asian markets for primary periodic paralysis.

Keveyis is Xeris Biopharma Holdings, Inc.'s proven therapy for primary periodic paralysis. In 2024, Keveyis contributed to total expected revenues between $190 million - $200 million for the full year. For the nine months ended September 30, 2025, Keveyis net revenue was $34.9 million, representing a decrease of approximately 9% compared to the same period in 2024. For the first half of 2025, Keveyis net revenue was $22.9 million, a 13% decrease year-over-year. Exploring licensing deals in Asian markets would target new territories for this established product. The company has shown a willingness to use licensing agreements, such as the one for Gvoke in Europe, and platform agreements with companies like Regeneron and Beta Bionics.

Here is a snapshot of the U.S. product revenue performance for the nine months ended September 30, 2025, which informs the financial capacity for Market Development initiatives:

The company reported an Adjusted EBITDA of $17.4 million for the third quarter of 2025.

You should review the status of the international regulatory filings for Recorlev in Canada and Australia, as that is a clear, actionable step for Market Development that is currently unquantified.

Xeris Biopharma Holdings, Inc. (XERS) - Ansoff Matrix: Product Development

You're looking at the core of Xeris Biopharma Holdings, Inc.'s future growth, which sits squarely in developing new products and expanding the utility of existing platforms. This is where the capital you see flowing into Research and Development (R&D) is aimed.

The most significant near-term catalyst is XP-8121, the once-weekly subcutaneous injection for hypothyroidism. Xeris Biopharma Holdings has stated the plan is to initiate the Phase 3 clinical trial for XP-8121 in 2026. This trial is designed to study 1,000 patients over 54 weeks comparing the candidate drug against traditional levothyroxine. The company is targeting a New Drug Application (NDA) approval from the U.S. Food & Drug Administration in 2030, with peak net revenue potential estimated between $1 billion to $3 billion by 2035.

The investment supporting this advancement is visible in the financial reporting. For the nine months ended September 30, 2025, R&D expenses increased by $3.8 million or 20% compared to the same period last year. Even in the third quarter of 2025 alone, R&D expenses rose $1.6 million or 27% year-over-year, reflecting continued investment in XP-8121 and platform development.

The XeriSol technology is already proving its worth through partnerships. Xeris Biopharma Holdings successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems, which triggered a milestone payment of $3 million in the fourth quarter of 2024. This confirms the platform's capability for complex drug delivery systems, which is the basis for future development, including the collaboration with Beta Bionics for their bi-hormonal pumps.

For Recorlev, which is already a commercial success with revenue growing 136% year-over-year in the second quarter of 2025, the focus shifts to maximizing its current exclusivity window. Recorlev received seven years of orphan-drug market exclusivity from the FDA, starting December 30, 2021. The company is investing R&D capital, as evidenced by the overall R&D spend increase, to explore new indications, which would help extend the value derived from this rare disease designation, which is further protected by patent exclusivity extending to at least March 2040.

The existing product Keveyis, while facing generic competition since 2022, represents an opportunity for technology extension. The goal here is to create new, patient-friendlier delivery systems using the proprietary XeriSol technology. Keveyis maintained a similar number of patients on therapy as Q3 2024. Applying XeriSol to this established therapy could improve patient compliance or expand its use profile.

Beyond these specific assets, Xeris Biopharma Holdings is advancing early-stage programs leveraging the XeriJect platform. XeriJect is specifically designed for biologics, such as monoclonal antibodies, allowing for ultra-concentrated suspensions for subcutaneous injections. The company has multiple early-stage programs leveraging both XeriSol and XeriJect for partners. For instance, Xeris partnered with Regeneron in March 2023 to use XeriJect for two monoclonal antibodies.

Here's a look at the investment and performance context surrounding these development efforts as of late 2025:

The company's overall financial health supports these internal investments. Total revenue guidance for the full year 2025 was updated to $285-$290 million. The net loss for the nine months ending September 30, 2025, was $10.5 million or ($0.07) per share, a 79% improvement versus the prior year period.

The product development focus can be summarized by the platform and pipeline assets:

• XP-8121: Phase 3 trial planned for 2026.
• XeriSol: Successfully used for glucagon formulation, triggering a $3 million milestone.
• Recorlev: Seven years of ODE from December 30, 2021.
• XeriJect: Used in partnership with Regeneron for two monoclonal antibodies.
• Keveyis: Maintaining patient base while exploring XeriSol application.

Finance: review the Q4 2025 R&D spend projection against the $3.8 million YTD increase to ensure sufficient capital remains for the 2026 XP-8121 trial initiation.

Xeris Biopharma Holdings, Inc. (XERS) - Ansoff Matrix: Diversification

You're looking at Xeris Biopharma Holdings, Inc.'s path beyond its current commercial base of Gvoke, Recorlev, and Keveyis. Diversification here means pushing the proprietary technology platforms-XeriJect and XeriSol-into new molecules, new therapeutic areas, and new geographies, all while leveraging the recent financial strength.

The third quarter of 2025 showed a significant financial foundation to support this. Total product revenue hit $74 million, a 40% increase year-over-year, with Recorlev alone bringing in $37 million, up 109% from the prior year. Furthermore, Xeris Biopharma Holdings, Inc. reported a net income of $0.6 million for the quarter, a major swing from the net loss of $15.7 million in the third quarter of 2024, and achieved an Adjusted EBITDA of $17.4 million.

This financial footing supports aggressive diversification strategies, even as Research and Development expenses for the quarter were $7.5 million, up 27% compared to the prior year.

Technology Platform Expansion and New Molecule Licensing

Securing new global licensing deals for XeriJect in non-endocrine, large-molecule therapy is about validating the platform beyond current partnerships. The existing XeriJect deal with Amgen for a subcutaneous formulation of teprotumumab (TEPEZZA) already sets a precedent for large molecules in a rare disease area, offering Xeris Biopharma Holdings, Inc. potential for $75 million in development and regulatory milestones, plus escalating single-digit royalties.

The XeriJect platform itself is engineered for high loading: XeriJect suspensions maximize drug loadings at greater than 400mg/mL, enabling small volume subcutaneous injections.

The co-development with Regeneron using XeriJect for a novel therapeutic is already in place, involving two undisclosed monoclonal antibodies. This is a direct move into new product development leveraging existing technology.

Here's a look at the existing technology licensing validation:

Global Market Capture for XP-8121

Planning for international regulatory submissions for XP-8121 aims to capture the global hypothyroidism market. XP-8121 is an investigational, ready-to-use liquid levothyroxine sodium formulation for once-weekly subcutaneous injection, utilizing the XeriSol technology.

The timeline for this market expansion is concrete:

• USPTO Notice of Allowance issued for XP-8121 patent (December 1, 2025).
• Phase 3 clinical trial planned for 2026.
• 1,000 patients to be studied over 54 weeks in Phase 3.
• Targeting New Drug Application approval from the FDA in 2030.
• Potential sales target of $1 billion to $3 billion by 2035.

The company has stated that the necessary step up in R&D and commercialization investments to bring XP-8121 to market do not require external financing or partnerships, as they expect to remain positive on Adjusted EBITDA.

New Therapeutic Area Entry and R&D Focus

Acquiring a commercial-stage asset in a completely new rare disease area, like oncology or pulmonology, represents the most aggressive diversification step, moving into new markets with established revenue streams. The company's nine-month R&D expenses through September 30, 2025, increased by $3.8 million, or 20%, supporting pipeline and technology platform development.

Establishing a new R&D center focused defintely on non-injectable drug delivery platforms would be a major strategic shift, moving beyond the core XeriSol and XeriJect injectable expertise. The current R&D spend supports both XP-8121 and ongoing technology platform development.

Key financial metrics supporting investment capacity:

• Full Year 2025 Total Revenue Guidance: $285 million to $290 million.
• Q3 2025 Gross Margin: 85%.
• Q3 2025 SG&A expenses: $46.5 million (a 3% increase year-over-year).

Finance: draft 13-week cash view by Friday.